L’ivermectine (Stromectol) est un antiparasitaire dont l’action repose sur la liaison sélective aux canaux chlore activés par le glutamate présents dans les cellules nerveuses et musculaires des parasites. Cette fixation entraîne une augmentation du flux de chlore, provoquant une hyperpolarisation et une paralysie irréversible. L’ivermectine est active contre la gale, l’onchocercose et certaines strongyloïdoses. Sa biodisponibilité orale est variable, augmentée par la prise alimentaire, et son élimination est principalement fécale via un métabolisme hépatique. Elle ne traverse pas la barrière hémato-encéphalique, ce qui limite les effets neurologiques chez l’homme. Les précautions concernent l’interaction avec les inhibiteurs du CYP3A4, ainsi que les réactions inflammatoires dues à la destruction massive des parasites. Dans les documents de référence, stromectol prix est associé à des protocoles précis adaptés aux différentes infestations, avec une attention particulière sur la sécurité d’emploi en cas d’immunodépression.

Untitled document

PAD VOLUME I
Table of Contents
INTRODUCTION. 7
THE DISEASE. 7
SYMPTOMS AND CONSEQUENCES. 8
INTERMITTENT CLAUDICATION IS UNCOMMON. 8
PAD IS NOT ASYMPTOMATIC. 10
MORTALITY. 11
Heart Attack and Stroke-The Main Causes of Death . 11
High Five- and 10-Year Mortality. 11
AN INDICATOR OF SILENT CARDIOVASCULAR AND CEREBROVASCULAR
DISEASE. 13
PAD SEVERITY PREDICTS CARDIOVASCULAR MORBIDITY AND MORTALITY. 14
RISK FACTORS. 15
Age . 16
Smoking. 17
Diabetes . 17
Hypertension. 18
Cholesterol. 18
Race . 19
MULTIPLE RISK FACTORS INCREASE THE RISK. 19
WOMEN AND PAD. 20
DIAGNOSIS. 21
DISEASE SEVERITY ASSOCIATED WITH LOWER ABI. 21
PREVALENCE. 22
PAD IS A SIGNIFICANT MARKET OPPORTUNITY-14 MILLION PEOPLE. 23
Estimated Prevalence Based On Diabetic Population . 23
PAD TO INCREASE WITH THE GRAYING OF AMERICA. 25
PAD PREVALENCE COMPARED TO OTHER SERIOUS DISEASES. 25
PAD IS UNDERDIAGNOSED. 26
Less Than 20% of PAD Patients Estimated to Have Been Diagnosed . 27
New Education and Awareness Programs Leading to Increased Numbers Diagnosed . 29
TREATMENTS. 30
Risk Factor Modification. 30
Supervised Exercise Program. 30
Drug Therapy. 31
ATHEROSCLEROSIS-AN INFLAMMATORY DISEASE. 31
Vulnerable Plaque . 33
Blood Clots . 33
ANTIHYPERTENSIVES. 34
ACE Inhibitors and Angiotensin Receptor Blockers (Antagonists) . 34
Angiotensin Receptor Blockers. 36
DIABETIC PATIENTS. 36
REDUCING THE RISK OF BLOOD CLOTS. 37
LIPID REDUCTION. 39
Statins . 39
Muscle Myopathy . 40
Heart Protection Study. 41
Zetia-A New Class of Cholesterol Medication . 41
Other Lipid-Lowering Agents-Fibrates and Bile Acid Sequestrants. 42
Niacin. 43
CHOLESTEROL REDUCTION AND VASCULAR REMODELING. 44
PAD DYSLIPIDEMIA SIMILAR TO ATHEROGENIC DYSLIPIDEMIA. 46
NEW OPPORTUNITIES- TARGETED DRUG THERAPY FOR PAD. 47
NEW RISK FACTORS. 49
Lipoprotein (a). 49
Homocysteine. 50
Inflammatory Factors . 50
C-Reactive Protein. 51
CLAUDICATION THERAPIES. 52
PROGRESSION OF PAD AND PERCENTAGE OF PATIENTS NEEDING
TREATMENT. 53
PAD UNDERTREATED. 54
LARGE POTENTIAL MARKETS FOR DRUG THERAPY. 55
Market for Claudication Therapy. 59
Market for Antihypertensives. 59
Market for Cholesterol-Lowering Therapy. 62
Market for Antiplatelets. 65
VALUATION TABLE. 69
COMPANY INFORMATION AND FINANCIAL DATA (ALPHABETICAL LIST). 71
REFERENCES. 97
LIST OF STUDIES/ACRONYMS. 107
INDEX OF TABLES AND FIGURES. 111
GLOSSARY. 117
TRADEMARKS. 131
DISCLOSURE STATEMENT. 133
CONTACT INFORMATION. 135

Source: http://thesagegroup.us/VolumeI/VI_TOC.pdf